BRAF and neoplasm: To be considered “low risk,” patients must not have any known high-risk factors such as tumor larger than 4 cm, extrathyroidal extension (ETE), tall cell differentiation, and significant lymph node involvement (more than 5 central lymph node metastases and/or lateral lymph node metastasis).2 Additional pathologic features important in postoperative risk stratification are lymph invasion and angio-invasion, BRAF mutation status, and tumor multifocality.